Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Bone Marrow Transplant. 2021 Sep 28;56(12):3068–3077. doi: 10.1038/s41409-021-01450-3

Table 5:

Multivariate Analysis of outcomes. Comparison of Adverse vs. Favorable/Intermediate* aELN risk groups

HR (95% CI) p-value
Overall survival 1.39 (1.22–1.57) <0.001
Disease-free survival 1.35 (1.20–1.51) <0.001
Relapse 1.47 (1.28–1.70) <0.001
Non-relapse mortality 1.01 (0.81–1.19) 0.89
Grade II-IV acute GVHD 1.04 (0.91–1.19) 0.53
Chronic GVHD 0.95 (0.83–1.08) 0.42
*

Reference group

Abbreviations: GVHD, graft-vs.-host disease; aELN, adapted European LeukemiaNet.